Study on Pharmacokinetics of Single Injection of Ciprofol in Patients With Moderate to Severe Hypoproteinemia

Launched by XIE KANGJIE · May 21, 2024

Keywords

ClinConnect Summary

This clinical trial is studying how a single injection of a medication called Ciprofol behaves in the body of patients who have moderate to severe hypoproteinemia, which means they have low levels of protein in their blood. The researchers will measure the amount of Ciprofol in the blood at different times after the injection to understand how it is processed by the body. This study is currently recruiting participants aged 18 to 80 who weigh more than 45 kg and have a body mass index (BMI) between 20 and 24.

To be eligible for this trial, participants must have moderate to severe hypoproteinemia and be in good overall health (classified as ASA Class I or II). However, those with severe liver or kidney problems, allergies to certain substances like eggs or soy, or who are undergoing emergency surgery cannot participate. If you join the study, you can expect to receive a single injection of Ciprofol and have your blood tested at various times afterward. This research will help us learn more about Ciprofol and how it can be safely used in patients with low protein levels.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients with moderate to severe hypoproteinemia (albumin \< 30g/L, protein detection time uniformly within three days before surgery）
• • Weight greater than 45kg, BMI20-24
• • The ASA rating is Class I or Class II
• Exclusion Criteria:
• • Severe liver dysfunction
• • Severe renal dysfunction
• • Patients with ASA grade III and above
• • Known allergy to eggs, soy products, opioids and their relief drugs, propofol
• • Emergency surgery